Kornimate/medical-research-clean huggingface dataset:
scapular pnf versus shoulder strengthening exercises in patients with lateral epicondylitis.

Conditions: Lateral Epicondylitis

Summary: the purpose of this study is to compare between the effect of scapular proprioceptive neuromuscular facilitation versus shoulder and scapular strengthening exercise on pain, functional outcome and grip strength in patients with lateral epicondylitis.

there is no standard treatment for lateral epicondylitis, it is always a combination of physical therapy modalities aimed to reduce pain and increase the ability to return functional activities participation. accordingly, many researchers have added shoulder strengthening exercise to the rehabilitation plan for treating lateral epicondylitis. consequently, development of new concept of scapula motor control exercise using proprioceptive neuromuscular facilitation to add proximal stability to patients with lateral epicondylitis may be beneficial. we believe that this study can serve as a step toward documenting the evidence of scapular proprioceptive neuromuscular facilitation exercise in the treatment of patients with lateral epicondylitis which was not available before. patients with lateral epicondylitis will be recruited after approval of ethical committee of the faculty of physical therapy, cairo university. all participants will sign a written informed consent form. after group assignment, patients' demographics will be collected, and then assessment of pain, function and grip strength will be performed. the same assessment procedure will be conducted by the end of the treatment (by the end of the 12th visit). the study will be two comparative groups, pre-post experimental design, the subjects will be randomly assigned into one of two groups: * group (i) : will receive scapular proprioceptive neuromuscular facilitation exercises. * group (ii) : will receive shoulder strengthening exercises.

Eligibility criteria:
inclusion criteria: * patients will be included if they have the following criteria: * fifty-two male and female subjects. * patients complaining of chronic lateral epicondylitis (more than three months). * age between 20-50. exclusion criteria: * patients will be excluded if they had any of the following conditions: * received physiotherapy in last 3 months. * received corticosteroids injection in lateral epicondyle in last 3 months. * receiving anti-inflammatories medications on regular basis. * had neurologic problems in shoulder, neck and thoracic regions. * had history of rheumatic disease. * had cooperation difficulties due to cognitive disorders. all patients will be instructed to keep away from activities that aggravate the symptoms such as grasping, lifting, knitting and using a screwdriver during the treatment period.

Keywords: scapular pnf scapular proprioceptive neuromuscular facilitation exercise shoulder strengthening exercises
combination of almonertinib and concurrent chemoradiotherapy in unresectable stage iii nsclc

Conditions: NSCLC, Stage III

Summary: this is a prospective, open, single arm study to evaluate the efficacy and safety of the almonertinib combined with concurrent chemoradiotherapy in unresectable stage iii nsclc with egfr mutation


Eligibility criteria:
inclusion criteria: 1. age ≥18, male or female. 2. patients must provide written informed consent to participate in the study. 3. patients must have biopsy proven unresectable stage iii nsclc (ajcc 8th). 4. patients must has sensitizing egfr mutation (e.g. exon 19 deletion or exon 21 l858r). 5. patients receiving almonertinib for 3 months and achieved stable disease, partial response or completely response. 6. ecog score 0-1 7. demonstrate adequate organ function patients evaluated as cr, pr and sd were given concurrent chemoradiotherapy 3 months after targeted therapy exclusion criteria: 1. patients progress in 3 months after almonertinib treatment 2. patient can't tolerate radiotherapy or targeted therapy 3. pregnant or nursing women

Keywords: almonertinib chemoradiotherapy
the effect of therapeutic story on pain, fear and anxiety levels

Conditions: Pain; Burns; Fear; Anxiety

Summary: aim: the aim of this study was to evaluate the effect of therapeutic story on pain, anxiety, fear and physiological parameters in children undergoing burn dressing. methods: a randomised controlled trial was conducted between april 2023 and june 2024 with 60 patients who were admitted to the burn unit of a hospital in istanbul and met the inclusion criteria. patients in the story group (n=30) were listened to the digitised story during burn dressing, while patients in the control group (n=30) did not receive any intervention other than routine care. data were collected using the descriptive characteristics form, child anxiety scale-situation scale, child fear scale, wong-barker pain scale, parental satisfaction scale (vas) and physiological parameters form.


Eligibility criteria:
inclusion criteria: * - to be between 3-6 years old, * consideration of the first dressing of the child in the burn centre * 2nd degree superficial and deep burns (2nd degree burns requiring hospital treatment and high pain level) * percentage of burns below 10 per cent (light sedation for children with burn injuries above 10 per cent) * not having any chronic disease other than burns * the child's willingness to participate in the research * it is the absence of mental, communication problems and visual impairment. exclusion criteria: * • the child's dressing has been done in a burn center before * presence of 1st and 3rd degree burn areas * burn percentage is over 10%

Keywords: anxiety burn child pain fear
lumbar plexus block application in ultrasound-guided shamrock method

Conditions: Femoral Neck Fractures; Lumbosacral Plexus; Nerve Block

Summary: the more effective use of ultrasound in regional anaesthesia techniques has made different block applications possible. lumbar plexus block is also used for post-operative analgesia and surgical anaesthesia. currently, in-plane ultrasound-guided lpb is widely used in short-axis imaging and shamrock imaging.

the purpose of this use is to investigate the effectiveness of lumbar plexus block application applied with in-plane and out-of-plane methods accompanied by shamrock imaging.

Eligibility criteria:
inclusion criteria: * 18-90 years old * asa (american society of anaesthesiologist) score i-iii risk class * patients who will undergo femoral neck fracture operation. exclusion criteria: * local anaesthetic allergy * with bleeding diathesis disorder * mental disorders * allergic to the medicines used * previous cerebrovascular disease * body mass index above 30
ferrous sulphate supplement (v0355) in women with iron deficiency anaemia

Conditions: Iron Deficiency Anemia

Summary: the purpose of this study is to investigate the pharmacokinetics of serum iron after a single oral administration of 160 mg (2 tablets of 80 mg) v0355 in women with iron deficiency anaemia.


Eligibility criteria:
inclusion criteria: * women 18-45 years inclusive with iron deficiency anaemia * haemoglobin level between 85 g/l and 105 g/l * serum ferritin level \< 15 µg/l * d14 +/- 7 days of the menstruation cycle on the day of pharmacokinetic evaluation exclusion criteria: * anaemia related to other causes than iron deficiency and particularly inflammatory anaemia, anaemia due to marrow failure, haemopathy, haemoglobinopathies (sickle cell disease, thalassemia), haemolytic anaemia, anaemia due to acute haemorrhage, or anaemia related to chronic renal failure, * haemochromatosis or iron overload of secondary origin (blood transfusion), * long term treatment known to modify iron absorption, * gastro duodenal ulcer, * inflammatory bowel disease or any digestive disease which could modify iron absorption, * serious or progressive disease (cardiac, pulmonary, hepatic, renal, haematological, malignancy, autoimmune disease, infectious disease or neuropsychiatric disorders), * surgery undergone within 1 month prior to selection visit or a surgery planned during the study realization.
identify proteomic biomarkers for outcome prediction of locoregional treatments for hcc

Conditions: Hepatocellular Carcinoma

Summary: this study will enroll patients with hepatocellular carcinoma being planned for tace or other standard of care treatment (such as denovo ablation or y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based x-aptamer library. no intervention is planned.

this is a prospective, non-blinded, multi-arm study. patients at 18 - 70 years old with liver cancer will be enrolled. the approach is to identify novel proteomic biomarkers for hcc patients treated with lipiodol tace, denovo ablation or y90 using beads-based x-aptamer library, then validate and create a biomarker panel that can be used to predict the outcome of hcc post treatment. lipiodol tace, denovo ablation, or y90 will be done as standard of care and the only thing done as research will be blood draws pre and post-tace.

Eligibility criteria:
inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent. 2. male or female aged 18-70years. 3. diagnosed with primary or metastatic liver cancer. 4. scheduled to undergo lipoidal tace, denovo ablation, or yttrium-90 (y90) radioembolization as part of standard of care. exclusion criteria: subjects who have received chemotherapy, radiation or surgery for hcc.
investigation of brain nitrogen in partial ornithine transcarbamylase deficiency (otcd) using 1 h mrs, dti, and fmri

Conditions: Ornithine Transcarbamylase Deficiency

Summary: the purpose of this study is to use various types of mri and cognitive testing to evaluate changes in the brain and cognitive function that occur in subjects with ornithine transcarbamylase deficiency (otcd) relative to healthy individuals

the overall goal of this project is to characterize metabolic, structural and cognitive changes in otcd using 1h mrs, dti, volumetric averaging and fmri with cognitive testing of executive function measures to validate biomarkers for the effect of ha and its treatment on the brain. the investigators will measure gln and mi in blood and brain (using 1h mrs) in affected participants, and mi in brain in controls, fractional anisotropy as a measure of white matter microstructural damage (by dti) and brain activation pathways alterations with tasks probing working memory (fmri). as a secondary outcome measure, the investigators will correlate the findings from neuroimaging with cognitive functioning. this protocol is based on the previous 5104 protocol, now includes children to evaluate the age and stage of disease on these indices in a cohort that is undergoing important developmental events against an age matched typically developing cohort.

Eligibility criteria:
inclusion criteria: subject inclusion criteria: 1. patients with otcd; 2. age range: 7-60 years 3. able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices) 4. subject has a documented full scale iq \> 70 control participant inclusion criteria: 1. healthy males and females without metabolic disease aged 7-60 years 2. subject has a documented full scale iq \> 70 exclusion criteria: subject exclusion criteria: 1. mental retardation (i.e., full scale iq\< 70) 2. age range \ 60 years 3. presence of ferromagnetic device(s) that preclude safe imaging 4. pregnant female control exclusion criteria: 1. subjects with a documented history of an intellectual deficit (i.e., full scale iq\< 70) 2. age range \ 60 years 3. presence of ferromagnetic device(s) that preclude safe imaging 4. pregnant female

Keywords: neuroimaging mri urea cycle hyperammonemia cognitive function ornithine transcarbamylase deficiency
to study gene expression of postburn hypertrophic scar

Conditions: Cicatrix, Hypertrophic

Summary: aim: to compare the gene expression of postburn hypertrophic scar with normal skin.

background: postburn hypertrophic scar (hs) remains a challenging problem. although varied clinical therapeutic methods have been used, none of them has been widely accepted as a standard care. as hypertrophic scar is hereditary, gene therapy can be a potential tool for scar treatment. to investigate the correlation between the clinical presentation of the hypertrophic scar and its gene expression, we propose an analysis of gene expression in the hypertrophic scar using dna microarray and real-time quantitative pcr. the study result may form the base of clinical treatment. methods and materials: thirty scar patients requiring surgical treatment in ntuh burn center will be enrolled into the study. inclusion criteria: (1) age between 20 and 80 (2) patients with postburn hypertrophic scar require surgical treatment. 1. hypertrophic scar and normal skin collection: under clinical trial informed consent of research ethic committee, scar and normal skin specimen of 1x1cm2 each will be collected and transported to tissue bank with a vacuum low temperature container. the specimen will be kept in a -80℃ refrigerator. 2. rna extraction from skin tissue: the rna extraction will be performed using kit available in the market. spectrophotometer and gel electrophoresis will be used to measure the purity and concentration of rna. 3. gene expression analysis: dna microarray and real-time quantitative pcr will be used to analyze rna expression of hypertrophic scar and normal skin. statistics: student's t-test will be used to compare statistically gene expression between hypertrophic scar and normal skin. p \< 0.05 will be considered as statistical significance.

Eligibility criteria:
inclusion criteria: * age20\~80, hypertrophic scar patient exclusion criteria: * no specific limitation
mesenchymal stem cell-derived pleiotropic factor in treating non-healing wounds

Conditions: Mesenchymal Stem Cell-derived Bioactivator for Treating Chronic Wounds

Summary: chronic wounds do not heal for prolonged periods of time with the significant financial burden on the healthcare system. it has become increasingly essential to improve our clinical treatments. the most promising potential treatment options rely on stem cell-based therapies. a large body of evidence indicates that mesenchymal stem cells can promote wound closure of chronic wounds in animal models and in preclinical studies. mscs efficacy depends mostly on their paracrine activity. all the bioactive factors and cytokines in mscs secretions constitute can be collected in the conditioned medium. in here, stem cell-derived conditioned medium was further made into a lyophilized powder. patients with chronic wounds were enrolled. the wounds in control group treated with fibroblast growth factor commonly used in clinical practice. the wounds in experimental group treated with lyophilized powder. the effectiveness and safety of lyophilized powder will evaluate for chronic wounds.


Eligibility criteria:
inclusion criteria: clinical diagnosis of chronic wounds; male or female over 17; psychologically stable and able to complete the experimental process. - exclusion criteria: wound greater than 10cm ×10cm; exposure to radiation or use of hormones, chemotherapy, growth factor dressings and immunosuppressants within 3 months; participated in other similar tests within 3 months; pregnant, or lactating women; severe infectious disease; severe heart, liver, and kidney dysfunction; had a history of cancer -
epidemiological characteristics of elderly trauma patients in zhejiang province and development of geriatric trauma short-term mortality prediction model

Conditions: Trauma Injury; Old Injury

Summary: this is a retrospective study. trauma patients aged 65 years or older will be included. the aims of this study are explore the epidemiological characteristics of elderly trauma patients in zhejiang province; establishment of early warning score system of elderly trauma death in zhejiang province; and horizontal comparison of the treatment level of elderly trauma in zhejiang province.


Eligibility criteria:
inclusion criteria: trauma patients aged 65 years or older exclusion criteria: secondary trauma due to other causes
a double-blind, placebo-controlled, dose ranging study of xanamem® in healthy elderly volunteers

Conditions: Mild Cognitive Impairment; Alzheimer&#39;s Disease

Summary: xanamem® is being developed as a potential drug for mild cognitive impairment in alzheimer's disease. this study drug has been designed to change the cortisol levels in the brain. cortisol is a naturally occurring hormone in the body. it is believed that reducing the level of cortisol will be a benefit in the treatment of mild cognitive impairment in alzheimer's disease. the purpose of this study in older volunteers is to investigate the smallest dose of xanamem® (5 mg or 10 mg) which works and to investigate which dose in this study will be used in the upcoming clinical trials in patients.


Eligibility criteria:
inclusion criteria: 1. male or female aged 50 to 80 2. body mass index 17.5 to \< 35 kg/m2, inclusive at the time of screening 3. mini-mental state score of ≥ 25 points at screening 4. must provide written informed consent exclusion criteria: 1. abnormalities in vital signs at screening or baseline 2. clinically significant abnormal hematology or biochemistry values, as determined by the investigator at screening and/or baseline. 3. previous clinically significant systemic illness or infection within the past 4 weeks prior to screening or baseline, as determined by the investigator 4. clinically significant ecg abnormalities 5. use of tobacco- or nicotine-containing products in the past month or unwillingness to abstain during study participation 6. participation in another clinical study of a drug or device 7. known allergy to the study drug (xanamem®) or any of the excipients 8. subjects who are likely to be unable to comply with the study schedule and/ or subjects with an inability to communicate well with the investigator 9. positive testing for human immunodeficiency virus (hiv), hepatitis b surface antigen, or hepatitis c antibodies at screening 10. subjects with a history of drug abuse or addiction in the past 5 years. 11. evidence of alcohol abuse (defined as greater than 21 standard units per week for males and greater than 14 standard units per week for females)

Keywords: cognitive function healthy volunteers emestedastat
standardized evaluation of subcutaneous glucose monitoring systems under routine environmental conditions

Conditions: Diabetes Mellitus, Type 1

Summary: the purpose of this study is to assess accuracy and reliability of the spidiman continuous glucose monitoring (cgm) sensor system with regard to values as measured by super gl and compare these results with similar evaluations of the medtronic minimed 640g system, the abbott freestyle libre flash sensor and the dexcom g4 platinum sensor in patients with type 1 diabetes.

the study is a single-center open-label study in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion (csii) or multiple daily injections (mdi) therapy. the study will include a total of 12 subjects.

Eligibility criteria:
inclusion criteria: * informed consent obtained after being advised of the nature of the study * male or female aged ≥18 years * type 1 diabetes for at least 6 months according to the world health organization (who) definition * treatment with multiple daily injections (mdi) or continuous subcutaneous insulin infusion (csii) for at least 3 months * body mass index (bmi) \< 35 kg/m² * willing and able to wear 5 cgm devices for the duration of the study and undergo all study procedures. * hba1c ≤ 86 mmol/mol exclusion criteria: * any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject * female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods * any mental condition rendering the subject incapable of giving his consent * subject is using a medication that significantly impacts glucose metabolism (oral steroids) except if stable for at least the last three months and expected to remain stable for the study duration * subject may not use acetaminophen (paracetamol) while participating in the study * has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the investigator would compromise the subject's safety or successful participation in the study. * subject is actively enrolled in another clinical trial * known adrenal gland problem, pancreatic tumour, or insulinoma * inability of the subject to comply with all study procedures * inability of the subject to understand the patient information. * subject donated blood in the last 3 months

Keywords: glucose monitoring system
evaluation of the performance and use of non-invasive glucose monitoring device

Conditions: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus

Summary: diabetes is a leading cause of death in the western world with medical costs increasing annually. there is no cure for diabetes, and blood glucose monitoring is a key component in diabetes treatment and management. self-monitoring of blood glucose levels is essential to the self-management of diabetes and has become widespread over the past decade. blood glucose determinations are currently done by invasive methods (finger tip pricking), followed by measuring the blood drop characteristics. the purpose of this trail is to demonstrate the performance and use of glucotrack device in measuring blood glucose levels. the rationale for development of the device is to improve the patient's quality of life by providing a device that is easily used and provides a painless measurement method, thereby leading to higher compliance, and to better managed diabetes

see brief summary

Eligibility criteria:
inclusion criteria: * type 1or 2 diabetes * anatomically suitable earlobe exclusion criteria: * subjects requiring dialysis * any conditions that may hamper good contact between the pec and the earlobe * pregnancy * nursing mothers

Keywords: glucose monitoring glucotrack self glucose monitoring